Colombian tilapia processor's HACCP plan omits Clostridium botulinum and drug-residue hazards, FDA says after remote assessment.
What happened
FDA carried out a Foreign Remote Regulatory Assessment (an off-site review of the plant's records and procedures) of the firm's seafood processing facility in Colombia from May 23 through May 29, 2023. At the end, the investigator gave the firm a list of the deviations found, and FDA says it has received no response. FDA found the firm's HACCP plan for fresh and frozen whole or filleted tilapia does not list Clostridium botulinum as a hazard at one processing step, the individual packages carry no "keep frozen" statement, and the plan does not address aquaculture drug or environmental contaminant hazards from receiving live fish.
What FDA found
The HACCP plan for tilapia does not list Clostridium botulinum, a bacterium that can grow in fish and produce a deadly toxin, as a food safety hazard at one of the processing steps.
21 CFR 123.6(a) and (c)(1)The individual packages have no label statement telling users to keep the product frozen.
21 CFR 123.6(a) and (c)(1)The firm takes in live tilapia from farms that may use aquaculture drugs, but the HACCP plan does not identify aquaculture drug residues or environmental contaminants as hazards at receiving.
21 CFR 123.6(a) and (c)(1)Because these requirements were not met, FDA deems the fish adulterated, meaning it was prepared, packed or held under conditions where it may have been made harmful to health.
21 U.S.C. ยง 342(a)(4) (Section 402(a)(4) of the Act); 21 CFR 123.6(g)The firm did not respond to the observations FDA left at the end of the assessment.
What FDA wants
FDA asks the firm to reply in writing within 15 working days outlining the corrections, with a revised HACCP plan and five consecutive days of completed monitoring records covering five production date codes. If all corrections cannot be finished in that time, the firm must explain the delay and say when the rest will be done.
Who should pay attention
- U.S. importers and distributors of Colombian tilapia
- brands and retailers buying frozen tilapia fillets from Latin American processors
- food safety teams at seafood buyers who rely on supplier HACCP plans
This is a summary. Read the original letter on fda.gov.